
	Three Months Ended October 31,				Six Months Ended October 31,
	2025		2024		2025		2024
General and administrative	$	191	$	(95)	$	339	$	90
Sales and marketing	14		51		26		91
Research and development	32		3		64		7
Cost of oncology revenue	12		50		28		79
Total stock-based compensation expense	$	249	$	9	$	457	$	267

For the three and six months ended October 31, 2025, stock-based compensation expense for research and development includes approximately $31,000 and $61,000 respectively, for options granted by the Company's wholly-owned subsidiary, Corellia, to certain of its employees.

The Company has in place a 2021 Equity Incentive Plan and 2010 Equity Incentive Plan as well as the 2023 Global Equity Incentive Plan which is specific to Corellia (collectively, the "Plans"). In general, these Plans provide for stock-based compensation to the Company’s employees, directors and non-employees. The 2010 and 2021 Plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.

As part of the 2021 Annual Shareholders Meeting, shareholders approved the adoption of the 2021 Equity Incentive Plan (“2021 Equity Plan”). The purpose of the 2021 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Incentive Stock Options; (iii) Restricted Stock Awards; and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2021 Equity Plan shall not exceed 2 million shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Company's Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant. As of October 31, 2025, approximately 355,000 shares were available for issue under this plan.

On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (“2010 Equity Plan”). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant. After February 2021, no more shares were available to be issued from this plan. As of October 31, 2025, approximately 787,000 options granted under the 2010 plan were still outstanding.

As part of the establishment of Corellia, the subsidiary's Board of Directors approved the adoption of the 2023 Global Equity Incentive Plan ("the Plan"). The purpose of the Plan is to grant (i) Non-statutory Stock Options; (ii) Incentive Stock Options; and/or (iii) Restricted Stock Awards (collectively, stock-based compensation) to its employees, directors and non-employees. Options expire no later than ten years from the date of grant. Options awards vest as follows, unless otherwise determined by the subsidiary's Board or Plan Administrator, twenty-five percent (25%) of the options grant on the first anniversary of the vesting commencement date (and in the absence of such determination, of date on which such Options were granted), and six and one-quarter percent (6.25%) of the options grant at the end of each subsequent three-month period thereafter over the course of the following three (3) years.


	Three Months Ended October 31,		Six Months Ended October 31,
	2025	2024	2025	2024
Expected term in years	0	6	6	6
Risk-free interest rates	—%	3.58% - 3.77%	4.08% - 4.50%	3.58% - 4.48%
Volatility	—%	59.47% - 59.57%	55.65% - 62.00%	59.47% - 62.72%
Dividend yield	—%	—%	—%	—%

The weighted average fair value of stock options granted during the three months ended October 31, 2025 and 2024 was $0.00 and $2.48, respectively, noting that no options were granted during the three months ended October 31, 2025. The weighted average fair value of stock options granted during the six months ended October 31, 2025 and 2024 was $4.33 and $2.49, respectively.

The weighted average fair value of stock options granted during the six months ended October 31, 2025 was $1,364.00. There have been no Corellia stock options granted prior to the first quarter of fiscal 2026 and no options were granted during the three months ended October 31, 2025.

Due to the absence of an active market for the Corellia's common stock, Corellia utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted, Corellia has considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock. Among other factors are Corellia's financial position and historical financial performance, the status of technological developments within its' research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company’s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.


	Directors and Employees	Non- Employees	Total	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2025	1,642,351	36,331	1,678,682	$	4.98	4.9	$	4,434,000
Granted	874,000	—	874,000	7.39		9.7
Exercised	(109,156)	—	(109,156)	2.11
Forfeited	(15,125)	—	(15,125)	7.04
Canceled	(8,375)	—	(8,375)	7.13


Outstanding, October 31, 2025	2,383,695	36,331	2,420,026	$	5.96	6.5	$	3,726,000

Vested and expected to vest as of October 31, 2025	2,383,695	36,331	2,420,026	$	5.96	6.5	$	3,726,000

Exercisable as of October 31, 2025	1,458,663	5,625	1,464,288	$	5.06	4.4	$	3,476,000

The remaining unrecognized stock-based compensation expense at October 31, 2025 was $3.8 million. Of this amount, $1.2 million relates to time-based awards with a remaining weighted average recognition period of 3.61 years and $888,000 related to market based awards with a remaining average recognition period of 2.2 years. The remaining $1.7 million of unrecognized stock-based compensation expense relates to performance-based awards for which expense will only be recognized when it becomes probable that the Company will achieve such defined financial targets. As of October 31, 2025 , there were 430,000 options that have these performance-based vesting provisions and are subject to forfeiture, in whole or in part, if these performance conditions are not achieved. Management assesses, on an ongoing basis, the probability of whether the performance criteria will be achieved and, if it is deemed probable, stock-based compensation expense is recognized over the relevant performance period.


	Directors and Employees	Non- Employees	Total	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2025	—	—	—	$	—	0	$	—
Granted	300	—	300	1,682.00		9.56





Outstanding, October 31, 2025	300	—	300	$	1,682.00	9.56	$	110,000

Vested and expected to vest as of October 31, 2025	300	—	300	$	1,682.00	9.56	$	110,000

Exercisable as of October 31, 2025	—	—	—	$	—	—	$	—

On March 29, 2023, the Board of Directors approved a share repurchase program authorizing the Company to purchase up to an aggregate of $5.0 million of the Company’s common stock. The share repurchase program is designed in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The shares may be purchased from time to time in the open market, as permitted under applicable rules and regulations, at prevailing market prices. The timing and amount of repurchases will depend on market conditions, share price, applicable legal requirements and other factors. The program does not obligate the Company to acquire a minimum number of shares. As of October 31, 2025, the Company had purchased 120,300 shares of its common stock, at an average price of $5.73 per share, totaling approximately $708,000 and leaving an available balance of approximately $4.3 million authorized by the Board for use in the program as of that date. The last purchase was made during fiscal year 2024.